Gossamer submits New Drug Application to the US Food and Drug Administration (FDA) for seralutinib in pulmonary arterial hypertension (PAH)

Gossamer Bio has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for seralutinib in pulmonary arterial hypertension (PAH). A New Drug Application is the formal application requesting that the Food and Drug Administration review a medicine to determine whether it may be approved for use in patients. To be followed.

Read the company press release at this link